Health Care & Life Sciences » Biotechnology | Celldex Therapeutics Inc.

Celldex Therapeutics Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Sales/Revenue
4,111.00
3,586.00
5,480.00
6,786.00
12,743.00
Cost of Goods Sold (COGS) incl. D&A
5,279.00
3,401.00
4,011.00
-
-
Gross Income
1,168.00
185.00
1,469.00
-
-
SG&A Expense
80,274.00
122,615.00
131,010.00
130,656.00
116,760.00
EBIT
81,442.00
122,430.00
129,541.00
127,962.00
109,327.00
Unusual Expense
-
-
-
4,954.00
12,200.00
Interest Expense
927.00
-
-
-
-
Pretax Income
81,550.00
118,080.00
127,197.00
128,530.00
117,313.00
Income Tax
-
-
-
-
24,282.00
Consolidated Net Income
81,550.00
118,080.00
127,197.00
128,530.00
93,031.00
Net Income
81,550.00
118,080.00
127,197.00
128,530.00
93,031.00
Net Income After Extraordinaries
81,550.00
118,080.00
127,197.00
128,530.00
93,031.00
Net Income Available to Common
81,550.00
118,080.00
127,197.00
128,530.00
93,031.00
EPS (Basic)
1.02
1.32
1.31
1.27
0.72
Basic Shares Outstanding
79,777.00
89,399.00
97,051.00
101,529.00
128,543.00
EPS (Diluted)
1.02
1.32
1.31
1.27
0.72
Diluted Shares Outstanding
79,777.00
89,399.00
97,051.00
101,529.00
128,543.00
EBITDA
78,497.00
119,029.00
125,530.00
123,870.00
104,017.00
Non-Operating Interest Income
819.00
4,350.00
2,344.00
4,386.00
4,214.00

About Celldex Therapeutics

View Profile
Address
Perryville III Building
Hampton New Jersey 08827
United States
Employees -
Website http://www.celldex.com
Updated 09/14/2018
Celldex Therapeutics, Inc. engages in the research, development, and manufacture of biopharmaceutical products. Its portfolio includes therapeutic antibodies, antibody drug conjugates, vaccines, and immune system modulators. The company's drug candidates include Glembatumumab vedotin, Varlilumab, CDX-1401, CDX-301, and Rintega.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.